Egrifta tesamorelin: Phase II data

A double-blind, U.S. Phase II trial in 60 obese patients with moderate growth hormone deficiency showed that once-daily 2 mg subcutaneous tesamorelin significantly reduced visceral fat by

Read the full 273 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE